LIM and SH3 protein 1, a promoter of cell proliferation and migration, is a novel independent prognostic indicator in hepatocellular carcinoma.
LIM and SH3 protein 1 (LASP-1) plays a significant role in the formation of several malignant tumours. However, the biological and clinical significances of LASP-1 in hepatocellular carcinoma (HCC) remain largely unknown. Using immunohistochemistry, we analysed LASP-1 expression in 144 clinicopathologically characterised HCC cases. Using gene and transfection and RNA interference, we investigated the effects of LASP-1 overexpression and depletion on tumour cellular behaviour in vitro. LASP-1 expression was detected in not only cytoplasm and but also nucleus of HCC and liver cells. The positive rates of both cytosolic and nuclear LASP-1 expression in HCC were higher than adjacent non-tumourous tissues. Statistical analysis showed that heterogeneous LASP-1 expression is associated with hepatitis B surface antigen (HBsAg) and serum alpha-fetoprotein (AFP) level of HCC patients. A significant trend was identified between cytosolic LASP-1 overexpression in HCC and worsening clinical prognosis. Multivariate survival analysis showed that cytosolic LASP-1 expression was recognised as an independent prognostic factor of patient's survival. In vitro study showed LASP-1 promoted cell proliferation and migration, and resulted in aggressive phenotypes of cancer cells. LASP-1 is a valuable marker of HCC progression. High cytosolic LASP-1 expression is associated with poor overall survival in HCC patients.
Department of Medical Oncology, Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou, China.
Hui
H
Wang
Weidong
W
Li
Xuejun
X
Jin
Shuzhong
S
Cui
Liang
L
Zhao
D048868:Adaptor Proteins, Signal Transducing / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D017209:Apoptosis; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D016022:Case-Control Studies; D002448:Cell Adhesion; D002453:Cell Cycle; D002465:Cell Movement; D002467:Cell Nucleus; D049109:Cell Proliferation; D002478:Cells, Cultured; D003593:Cytoplasm; D003598:Cytoskeletal Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006514:Hepatitis B Surface Antigens / Q000378:metabolism; D022781:Hepatocytes; D006801:Humans; D007124:Immunoenzyme Techniques; D060588:LIM Domain Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D034741:RNA, Small Interfering / Q000235:genetics; D015996:Survival Rate
D048868:Adaptor Proteins, Signal Transducing; D003598:Cytoskeletal Proteins; D006514:Hepatitis B Surface Antigens; C096353:LASP1 protein, human; D060588:LIM Domain Proteins; D034741:RNA, Small Interfering